Angiologix, Inc., founded as a medical diagnostic device company, focuses on providing non-invasive cardiovascular diagnostic products. Their core mission is to enhance the accuracy and accessibility of cardiovascular disease diagnosis and monitoring through innovative technology. Angiologix's products are designed for point-of-care testing of endothelial dysfunction, primarily serving physician-specialists in diagnosing cardiovascular diseases and monitoring therapy effectiveness.

Acquired by Everist Genomics in 2011, Angiologix has made significant strides in the medical diagnostics field. The acquisition has bolstered their capabilities and market reach. Notable achievements include the development of advanced diagnostic tools that have improved non-invasive testing methods, impacting patient care positively. The company's contributions have been instrumental in advancing cardiovascular diagnostics, making significant improvements in the early detection and management of cardiovascular conditions.